Complement–targeted molecular agents for generalized myasthenia gravis ; C5 inhibitors

Abstract

The Myasthenia Gravis (MG) Clinical Practice Guideline 2014 set a treatment goal of “MM-or-better-5mg” and indicated an “Early fast-acting treatment strategy.” In May of 2022, the MG/Lambert–Eaton Myasthenia Syndrome Clinical Practice Guideline 2022 was published and included the complement C5 inhibitor Eculizumab and newly clarifies the definition of refractory. In Japan, a new complement C5 inhibitor, Ravulizumab, has been approved and clinical trials of Zilcoplan are underway. In the future, it is expected to further improve the QOL of patients.